{
    "body": "Is nicotinamide effective for skin cancer prevention?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/25561219", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24798949", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19804594", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23349012"
    ], 
    "ideal_answer": [
        "Yes, oral nicotinamide is safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012878", 
        "http://www.disease-ontology.org/api/metadata/DOID:3451", 
        "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4273660", 
        "http://www.disease-ontology.org/api/metadata/DOID:4159", 
        "http://www.biosemantics.org/jochem#4273660"
    ], 
    "type": "yesno", 
    "id": "56c03d1fef6e39474100001a", 
    "snippets": [
        {
            "offsetInBeginSection": 174, 
            "offsetInEndSection": 341, 
            "text": "Nicotinamide (vitamin B3) has been shown to have protective effects against damage caused by UV radiation and to reduce the rate of new premalignant actinic keratoses.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1151, 
            "offsetInEndSection": 1820, 
            "text": "ESULTS: At 12 months, the rate of new nonmelanoma skin cancers was lower by 23% (95% confidence interval [CI], 4 to 38) in the nicotinamide group than in the placebo group (P=0.02). Similar differences were found between the nicotinamide group and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39]lower rate with nicotinamide, P=0.12) and new squamous-cell carcinomas (30% [95% CI, 0 to 51] lower rate, P=0.05). The number of actinic keratoses was 11% lower in the nicotinamide group than in the placebo group at 3 months (P=0.01), 14% lower at 6 months (P<0.001), 20% lower at 9 months (P<0.001), and 13% lower at 12 months (P=0.001).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2040, 
            "offsetInEndSection": 2192, 
            "text": "CONCLUSIONS: Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 70, 
            "offsetInEndSection": 281, 
            "text": "Nicotinamide is a safe, widely available vitamin that reduces the immune suppressive effects of UV, enhances DNA repair in keratinocytes and has shown promise in the chemoprevention of non-melanoma skin cancer. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24798949", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 871, 
            "offsetInEndSection": 1005, 
            "text": " In summary, nicotinamide, by enhancing DNA repair in melanocytes, is a potential agent for the chemoprevention of cutaneous melanoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24798949", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 156, 
            "offsetInEndSection": 385, 
            "text": "Recent double-blinded randomized controlled Phase 2 studies in heavily sun-damaged individuals have shown that oral nicotinamide significantly reduces premalignant actinic keratoses, and may reduce new non-melanoma skin cancers. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349012", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 201, 
            "offsetInEndSection": 357, 
            "text": "Nicotinamide (vitamin B3) prevents UV-induced immunosuppression and carcinogenesis in mice, and solar-simulated (ss) UV-induced immunosuppression in humans.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19804594", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1714, 
            "offsetInEndSection": 1940, 
            "text": "These results show that nicotinamide enhances two different pathways for repair of UV-induced photolesions, supporting nicotinamide's potential as an inexpensive, convenient and non-toxic agent for skin cancer chemoprevention.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349012", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 383, 
            "offsetInEndSection": 611, 
            "text": "Recent double-blinded randomized controlled Phase 2 studies in heavily sun-damaged individuals have shown that oral nicotinamide significantly reduces premalignant actinic keratoses, and may reduce new non-melanoma skin cancers.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23349012", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1821, 
            "offsetInEndSection": 2193, 
            "text": "No noteworthy between-group differences were found with respect to the number or types of adverse events during the 12-month intervention period, and there was no evidence of benefit after nicotinamide was discontinued.CONCLUSIONS: Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 174, 
            "offsetInEndSection": 612, 
            "text": "Nicotinamide (vitamin B3) has been shown to have protective effects against damage caused by UV radiation and to reduce the rate of new premalignant actinic keratoses.METHODS: In this phase 3, double-blind, randomized, controlled trial, we randomly assigned, in a 1:1 ratio, 386 participants who had had at least two nonmelanoma skin cancers in the previous 5 years to receive 500 mg of nicotinamide twice daily or placebo for 12 months. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1333, 
            "offsetInEndSection": 1597, 
            "text": "Similar differences were found between the nicotinamide group and the placebo group with respect to new basal-cell carcinomas (20% [95% CI, -6 to 39]lower rate with nicotinamide, P=0.12) and new squamous-cell carcinomas (30% [95% CI, 0 to 51] lower rate, P=0.05). ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 2021, 
            "offsetInEndSection": 2160, 
            "text": "Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26488693", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 133, 
            "text": "Nicotinamide has shown potential as a safe and effective intervention for the prevention of malignant and premalignant skin lesions.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25561219", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1749, 
            "offsetInEndSection": 1853, 
            "text": "Nicotinamide, which protected against both UVB and UVA, is a promising agent for skin cancer prevention.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19804594", 
            "endSection": "abstract"
        }
    ]
}